CD276 Antikörper (AA 100-300)
Kurzübersicht für CD276 Antikörper (AA 100-300) (ABIN7869823)
Target
Alle CD276 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 100-300
-
Verwendungszweck
- CD276 Antibody / B7-H3
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 100-300) from the human protein was used as the immunogen for the CD276 antibody.
-
Isotyp
- IgG1, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the CD276 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the CD276 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- CD276
-
Andere Bezeichnung
- CD276
-
Hintergrund
- T cell activation and immune function are regulated by the innate immune system through positive and negative costimulatory molecules. One such molecule, B7-H3 (B7-homolog 3, also designated B7RP-2) belongs to the B7 immunoglobulin superfamily. Soluble B7-H3 binds a putative receptor on activated T-cells that is distinct from CD28, CTLA-4, ICOS and PD-1. Widely expressed on nonlymphoid tissues, B7-H3 costimulates proliferation of both CD4+ and CD8+ T cells. The ability of B7-H3 to stimulate Th1 and cytotoxic-T cell responses suggest that it may have antitumor activity. B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, implicating B7-H3 as a potential therapeutic tool.
-
UniProt
- Q5ZPR3
-
Pathways
- Cancer Immune Checkpoints
Target
-